Related Experiment Video

Updated: Oct 3, 2026

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Platelet factor 4 as a marker of platelet activation in patients with acute myocardial infarction

V Dymicka-Piekarska1, H Kemona, M Mantur

  • 1Department of Clinical Laboratory Diagnostics, Medical Academy of Białystok.

Roczniki Akademii Medycznej W Bialymstoku (1995)
|November 20, 2001
PubMed

Insights

Platelet factor 4 (PF 4) levels change during myocardial infarction (MI). Thrombolytic therapy, including streptokinase, heparin, and aspirin, effectively inhibits platelet activation in MI patients.

Area of Science:

  • Cardiology
  • Hematology
  • Biochemistry

Background:

  • Platelets play a crucial role in the pathogenesis of ischemic heart disease and myocardial infarction (MI).
  • Platelet activation leads to the release of alpha granule proteins, such as platelet factor 4 (PF 4).
  • PF 4 serves as a marker for platelet activation.

Purpose of the Study:

  • To evaluate the dynamics of PF 4 in patients with acute myocardial infarction (MI).
  • To assess the influence of disease duration and treatment type on PF 4 levels.
  • To investigate the effect of thrombolytic therapy on platelet activation markers.

Main Methods:

  • Investigated 29 patients with acute MI, divided into two treatment groups (heparin/aspirin vs. streptokinase/heparin/aspirin).
  • Included a control group of 21 healthy subjects.
  • Measured PF 4 concentration on days 1, 3, 5, 8, and 11 post-MI using an immunoenzymatic method.

Main Results:

  • Observed changes in PF 4 levels during the course of myocardial infarction.
  • Demonstrated that thrombolytic therapy significantly inhibits platelet activation, as indicated by PF 4 levels.
  • Treatment with streptokinase, heparin, and aspirin showed a greater inhibition of platelet activation compared to heparin and aspirin alone.

Conclusions:

  • Platelet factor 4 dynamics reflect platelet activation status in acute myocardial infarction.
  • Thrombolytic therapy is effective in reducing platelet activation during MI.
  • The findings support the importance of antiplatelet and thrombolytic strategies in managing acute myocardial infarction.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...